LDHA-mediated metabolic reprogramming: a key driver of tumor malignancy
Abstract
Metabolic reprogramming is one of the core hallmarks of malignant tumors, among which the abnormally enhanced glycolysis driven by the Warburg effect constitutes a critical aspect of tumor metabolic remodeling. LDHA is abnormally highly expressed in various tumors, and its expression level is closely related to tumor malignancy. The high expression of LDHA is not limited to overall elevation but also exhibits spatial heterogeneity. LDHA expression is significantly higher in highly invasive tumor edge regions compared to low-invasive regions. LDHA maintains high glycolytic flux by catalyzing the conversion of pyruvate to lactate while regenerating NAD+, rapidly producing ATP to meet the energy demands of rapid tumor cell proliferation. Lactate produced through high glycolytic flux can be taken up by cancer-associated fibroblasts (CAFs) via MCT1 and enter the tricarboxylic acid cycle, promoting CAF proliferation. LDHA expression levels are positively and significantly correlated with intracellular lactate concentrations, and lactate, as the direct substrate source for histone lactylation modifications, changes in its abundance directly regulate histone lactylation levels. Lactate acts as an alternative energy substrate, providing fuel for oxidative tumor cells or tumor-associated stromal cells via monocarboxylate transporter (MCT1/4)-mediated lactate shuttle, forming a metabolic symbiosis network. The acidification of the tumor microenvironment, directly inhibiting T cell function, promoting T cell differentiation toward regulatory T cells, upregulating the expression of inhibitory receptors on the T cell surface to induce T cell exhaustion, and interfering with the formation of memory T cells. It also promotes macrophage polarization from the pro-inflammatory M1 type to the immunosuppressive M2 type, enhancing their tumor-promoting growth, angiogenesis, and tissue remodeling functions. Currently, LDHA inhibitors (e.g., FX-11 and GSK2837808A) and MCT1 inhibitors (e.g., AZD3965) have shown preclinical potential in suppressing tumor growth, reversing immunosuppression, and sensitizing conventional therapies. Some of these agents have already advanced into early-stage clinical trials. However, this strategy still faces challenges including enhanced tumor metabolic plasticity, on-target toxicity, and a lack of predictive biomarkers. Future research should focus on optimizing combination therapy strategies, elucidating mechanisms of metabolic adaptation, and enabling precise patient selection, thereby advancing novel therapeutic approaches based on lactate metabolism intervention toward clinical translation.
Related
- HIF-1α-mediated metabolic reprogramming in hypoxia-driven tumor metastasis
- Mitochondrial Metabolic Reprogramming in Macrophages: A Key Driver of Rheumatoid Arthritis.
- KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma
- Hypoxia-inducible factor-1α–mediated metabolic reprogramming in sepsis-associated organ dysfunction: organ-specific metabolic mismatch and therapeutic perspectives
- Mechanistic insights on mogrosides as bifunctional regulators of metabolic reprogramming and immune modulation in tumor microenvironment
BibTeX
@article{zhang2026ldhamediated,
title = {{LDHA-mediated metabolic reprogramming: a key driver of tumor malignancy}},
author = {Yu-ling Zhang and Qiu-feng Liu and Pei Chen},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1993212},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1993212},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - LDHA-mediated metabolic reprogramming: a key driver of tumor malignancy
AU - Yu-ling Zhang
AU - Qiu-feng Liu
AU - Pei Chen
PY - 2026
DA - 2026/11/04
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1993212
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1993212
AB - Metabolic reprogramming is one of the core hallmarks of malignant tumors, among which the abnormally enhanced glycolysis driven by the Warburg effect constitutes a critical aspect of tumor metabolic remodeling. LDHA is abnormally highly expressed in various tumors, and its expression level is closely related to tumor malignancy. The high expression of LDHA is not limited to overall elevation but also exhibits spatial heterogeneity. LDHA expression is significantly higher in highly invasive tumor edge regions compared to low-invasive regions. LDHA maintains high glycolytic flux by catalyzing the conversion of pyruvate to lactate while regenerating NAD+, rapidly producing ATP to meet the energy demands of rapid tumor cell proliferation. Lactate produced through high glycolytic flux can be taken up by cancer-associated fibroblasts (CAFs) via MCT1 and enter the tricarboxylic acid cycle, promoting CAF proliferation. LDHA expression levels are positively and significantly correlated with intracellular lactate concentrations, and lactate, as the direct substrate source for histone lactylation modifications, changes in its abundance directly regulate histone lactylation levels. Lactate acts as an alternative energy substrate, providing fuel for oxidative tumor cells or tumor-associated stromal cells via monocarboxylate transporter (MCT1/4)-mediated lactate shuttle, forming a metabolic symbiosis network. The acidification of the tumor microenvironment, directly inhibiting T cell function, promoting T cell differentiation toward regulatory T cells, upregulating the expression of inhibitory receptors on the T cell surface to induce T cell exhaustion, and interfering with the formation of memory T cells. It also promotes macrophage polarization from the pro-inflammatory M1 type to the immunosuppressive M2 type, enhancing their tumor-promoting growth, angiogenesis, and tissue remodeling functions. Currently, LDHA inhibitors (e.g., FX-11 and GSK2837808A) and MCT1 inhibitors (e.g., AZD3965) have shown preclinical potential in suppressing tumor growth, reversing immunosuppression, and sensitizing conventional therapies. Some of these agents have already advanced into early-stage clinical trials. However, this strategy still faces challenges including enhanced tumor metabolic plasticity, on-target toxicity, and a lack of predictive biomarkers. Future research should focus on optimizing combination therapy strategies, elucidating mechanisms of metabolic adaptation, and enabling precise patient selection, thereby advancing novel therapeutic approaches based on lactate metabolism intervention toward clinical translation.
SN - 2234-943X
ER -